Citations

Clear

16281 citation(s) found for "Yu, David".

Stripping versus ligation of vas deferens in microscopic denervation of spermatic cord in men with chronic orchialgia: A multicenter study
El‐Achkar, Adnan , Hammad, Muhammed , Barham, David , Service, C Austin, Hsieh, Tung- Chin, Mills, Jesse N. , Ziegelmann, Matthew , Smith, Ryan P. , Bernie, Helen L. , Egert, Melissa , Gross, Kelli, Pastuszak, Alex, Hotaling, James M. , Yafi, Faysal A. , Hammad, Muhammed A M , Patel, Darshan P. , Kianian, Reza , Eleswarapu, Sriram Venkata , Bryk, Darren J. , Raheem, Omer A. , Fendereski, Kiarad

Mayo Clinic

Andrology | April 19, 2024 | Volume: 13 | Issue: 2 | Pages: 268-274

10.1111/andr.13650 | PMID 38639020 Get It

AbstractBackgroundMicrodenervation of the spermatic cord (MSCD) is an effective treatment modality for men with intractable scrotal content pain. For patients not interested in preserving fertility, some centers advocate ligation of the vas during denervation, while others prefer stripping of the vas deferens to preserve the vasal artery, hence preserving vasculature to the testis and possibly decreasing post‐operative congestion pain.ObjectiveTo compare outcomes of patients with chronic orchialgia, who underwent MSCD by either stripping or ligating the vas deferens.Materials and methodsA retrospective chart review of 85 patients who underwent MSCD from 2017–2023 was performed. Patients’ demographics including history of prior surgical procedures were recorded. Response to surgery was evaluated as either complete resolution of pain, partial resolution of pain, or no improvement in pain.ResultsEighty‐five patients underwent MSCD with a median (interquartile range, IQR) age of 36 (25.5–46.5) years and median duration of pain of 16 (6–31) months. Thirty‐seven patients underwent stripping of vas, while 48 underwent ligation of vas during MSCD. Median follow up was 12 months. Twenty‐one (43.5%) patients had prior inguinal scrotal surgery in the ligation group compared to 5 (13.5%) in the stripping group, p = 0.003. The etiology of pain was similar between the groups. The response to MSCD between the two groups was similar, 67.6% of patients who underwent stripping had complete resolution of pain versus 66.7% of those who had ligation (p = 0.968), with similar rates of post‐operative complications (p‐value = 0.132).ConclusionsIn men with intractable chronic scrotal content pain with no interest in preserving fertility, ligation, or stripping of the vas deferens yields similar outcomes with regard to pain resolution. Both techniques are safe with no reports of any testicular atrophy.
Persistent Inequities in Intravenous Thrombolysis for Acute Ischemic Stroke in the United States: Results From the Nationwide Inpatient Sample
Sun, Philip Y. , Zheng, Ling , Lin, Michelle , Cen, Steven , Hammond, Gmerice, Maddox, Karen E. Joynt , Kim‐Tenser, May , Sanossian, Nerses , Mack, William J. , Towfighi, Amytis , Sun, Philip , Joynt Maddox, Karen E , Mack, William , Lin, Michelle P

Mayo Clinic

Journal of the American Heart Association | April 19, 2024 | Volume: 13 | Issue: 9 | Pages: No page available

10.1161/jaha.123.033316 | PMID 38639371 Get It

Background Despite its approval for acute ischemic stroke >25 years ago, intravenous thrombolysis (IVT) remains underused, with inequities by age, sex, race, ethnicity, and geography. Little is known about IVT rates by insurance status. Methods and Results We assessed temporal trends from 2002 to 2015 in IVT for acute ischemic stroke in the Nationwide Inpatient Sample using adjusted, survey ‐ weighted logistic regression. We calculated odds ratios for IVT for each category in 2002 to 2008 (period 1) and 2009 to 2015 (period 2). IVT use for acute ischemic stroke increased from 1.0% in 2002 to 6.8% in 2015 (adjusted annual relative ratio, 1.15). Individuals aged ≥85 years had the most pronounced increase during 2002 to 2015 (adjusted annual relative ratio, 1.18) but were less likely to receive IVT compared with 18‐ to 44‐year‐olds in period 1 (adjusted odds ratio [aOR], 0.23) and period 2 (aOR, 0.36). Women were less likely than men to receive IVT, but the disparity narrowed over time (period 1: aOR, 0.81; period 2: aOR, 0.94). Inequities in IVT resolved for Hispanic individuals in period 2 (aOR, 0.96) but not for Black individuals (period 2: aOR, 0.81). The disparity in IVT for Medicare patients, compared with privately insured patients, lessened over time (period 1: aOR, 0.59; period 2: aOR, 0.75). Patients treated in rural hospitals remained less likely to receive IVT than in urban hospitals; a more dramatic increase in urbanity widened the inequity (period 2, urban nonteaching versus rural: aOR, 2.58, period 2, urban teaching versus rural: aOR, 3.90). Conclusions IVT for acute ischemic stroke increased among adults. Despite some encouraging trends, the remaining disparities highlight the need for intensified efforts at addressing inequities.
Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity
Jacobson, Caron A. , Ghobadi, Armin , Ahmed, Sairah , Miklos, David B. , Perales, Miguel‐Angel , Fingrut, Warren , Pennisi, Martina , Gowda, Lohith , Abid, Muhammad Bilal , Hong, Sanghee , Kharfan‐Dabaja, Mohamed A. , Khurana, Arushi , Badar, Talha , Hu, Zhen‐Huan , Wang, Hailin , Baer, Anjani, Baro, Elande , Miao, Harry , Spooner, Clare, Xu, Hairong, Pasquini, Marcelo C. , Ghobadi, Armin , Ahmed, Sairah , Miklos, David B , Perales, Miguel-Angel , Fingrut, Warren B , Shadman, Mazyar , Majhail, Navneet S , Kharfan-Dabaja, Mohamed A , Badar, Talha , Bennani, N Nora , Herr, Megan M. , Pasquini, Marcelo , Abid, Muhammad Bilal , Locke, Frederick L. , Siddiqi, Tanya , Muñoz, Javier , Gauthier, Jordan , Shadman, Mazyar , Mirza, Abu‐Sayeef , Majhail, Navneet S. , Lin, Yi , Bennani, N. Nora

Mayo Clinic

Blood | April 18, 2024 | Volume: 143 | Issue: 26 | Pages: 2722-2734

10.1182/blood.2023023447 | PMID 38635762 Get It

Abstract Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Despite extensive data supporting its use, outcomes stratified by race and ethnicity groups are limited. Here, we report clinical outcomes with axi-cel in patients with R/R LBCL by race and ethnicity in both real-world and clinical trial settings. In the real-world setting, 1290 patients who received axi-cel between 2017 and 2020 were identified from the Center for International Blood and Marrow Transplant Research database; 106 and 169 patients were included from the ZUMA-1 and ZUMA-7 trials, respectively. Overall survival was consistent across race/ethnicity groups. However, non-Hispanic (NH) Black patients had lower overall response rate (OR, 0.37; 95% CI, 0.22-0.63) and lower complete response rate (OR, 0.57; 95% CI, 0.33-0.97) than NH White patients. NH Black patients also had a shorter progression-free survival vs NH White (HR, 1.41; 95% CI, 1.04-1.90) and NH Asian patients (HR, 1.67; 95% CI, 1.08-2.59). NH Asian patients had a longer duration of response than NH White (HR, 0.56; 95% CI, 0.33-0.94) and Hispanic patients (HR, 0.54; 95% CI, 0.30-0.97). There was no difference in cytokine release syndrome by race/ethnicity; however, higher rates of any-grade immune effector cell–associated neurotoxicity syndrome were observed in NH White patients than in other patients. These results provide important context when treating patients with R/R LBCL with CAR T-cell therapy across different racial and ethnic groups. ZUMA-1 and ZUMA-7 (ClinicalTrials.gov identifiers: #NCT02348216 and #NCT03391466, respectively) are registered on ClinicalTrials.gov.
Passive immunotherapies for the next influenza pandemic
Focosi, Daniele , Senefeld, Jonathon W. , Joyner, Michael J. , Sullivan, David , Senefeld, Jonathon W , Sullivan, David J , Joyner, Michael J , Focosi, Daniele , Franchini, Massimo , Pekosz, Andrew , Maggi, Fabrizio , Casadevall, Arturo

Mayo Clinic

Reviews in Medical Virology | April 18, 2024 | Volume: 34 | Issue: 3 | Pages: No page available

10.1002/rmv.2533 | PMID 38635404 Get It

AbstractInfluenzavirus is among the most relevant candidates for a next pandemic. We review here the phylogeny of former influenza pandemics, and discuss candidate lineages. After briefly reviewing the other existing antiviral options, we discuss in detail the evidences supporting the efficacy of passive immunotherapies against influenzavirus, with a focus on convalescent plasma.
Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses
Konstantinopoulos, Panagiotis A. , Cheng, Su–Chun, Lee, Elizabeth K. , Costa, Alexandre André Balieiro Anastácio da , Gulhan, D. , Hendrickson, Andrea E. Wahner , Kochupurakkal, Bose , Kolin, David L. , Kohn, Elise C. , Liu, Joyce F. , Penson, Richard T. , Stover, Elizabeth H. , Curtis, Jennifer, Sawyer, Hannah , Polak, Madeline , D’Andrea, Alan D. , Matulonis, Ursula A. , da Costa, Alexandre André B A , Gulhan, Doga , Wahner Hendrickson, Andrea E , D'Andrea, Alan , Shapiro, Geoffrey I , Matulonis, Ursula A , Konstantinopoulos, Panagiotis A , Chowdhury, Dipanjan , Färkkilä, Anniina , Shapiro, Geoffrey I.

Mayo Clinic

JCO Precision Oncology | April 18, 2024 | Volume: No volume available | Issue: 8 | Pages: No page available

10.1200/po.23.00635 | PMID 38635934 Get It

PURPOSE The multicenter, open-label, randomized phase 2 NCI-9944 study ( NCT02595892 ) demonstrated that addition of ATR inhibitor (ATRi) berzosertib to gemcitabine increased progression-free survival (PFS) compared to gemcitabine alone (hazard ratio [HR]=0.57, one-sided log-rank P = .044, which met the one-sided significance level of 0.1 used for sample size calculation). METHODS We report here the final overall survival (OS) analysis and biomarker correlations (ATM expression by immunohistochemistry, mutational signature 3 and a genomic biomarker of replication stress) along with post-hoc exploratory analyses to adjust for crossover from gemcitabine to gemcitabine/berzosertib. RESULTS At the data cutoff of January 27, 2023 (>30 months of additional follow-up from the primary analysis), median OS was 59.4 weeks with gemcitabine/berzosertib versus 43.0 weeks with gemcitabine alone (HR 0.79, 90% CI 0.52 to 1.2, one-sided log-rank P = .18). An OS benefit with addition of berzosertib to gemcitabine was suggested in patients stratified into the platinum-free interval ≤3 months (N = 26) subgroup (HR, 0.48, 90% CI 0.22 to 1.01, one-sided log-rank P =.04) and in patients with ATM-negative/low (N = 24) tumors (HR, 0.50, 90% CI 0.23 to 1.08, one-sided log-rank P = .06). CONCLUSION The results of this follow-up analysis continue to support the promise of combined gemcitabine/ATRi therapy in platinum resistant ovarian cancer, an active area of investigation with several ongoing clinical trials.
TOpCLASS Expert Consensus Classification of Perianal Fistulising Crohn’s Disease: A Real-world Application in a Serial Fistula MRI Cohort
Schroeder, Matthew , Abushamma, Suha , George, Alvin T , Ravella, Balakrishna , Hickman, John A. , Elumalai, Anusha, Ludwig, Daniel R. , Viswanath, Satish E. , Schroeder, Matthew K , Sebastian, Shaji , Ballard, David H , Deepak, Parakkal , Viswanath, Satish E , Hickman, John, Wise, Paul E. , Zulfiqar, Maria , Shetty, Anup S. , Luo, Chongliang , Ballard, David H. , Deepak, Parakkal

Mayo Clinic

Journal of Crohn's and Colitis | April 18, 2024 | Volume: 18 | Issue: 9 | Pages: 1430-1439

10.1093/ecco-jcc/jjae056 | PMID 38642332 Get It

Abstract Background and Aims Perianal fistuliing Crohn’s disease [PFCD] is an aggressive phenotype of Crohn’s disease defined by frequent relapses and disabling symptoms. A novel consensus classification system was recently outlined by the TOpCLASS consortium, which seeks to unify disease severity with patient-centred goals but has not yet been validated. We aimed to apply this to a real-world cohort and to identify factors that predict transition between classes over time. Methods We identified all patients with PFCD and at least one baseline and one follow-up pelvic MRI [pMRI]. TOpCLASS classification, disease characteristics, and imaging indices were collected retrospectively at time periods corresponding with respective MRIs. Results We identified 100 patients with PFCD, of whom 96 were assigned TOpCLASS Classes 1–2c at baseline. Most patients [78.1%] started in Class 2b, but changes in classification were observed in 52.1% of all patients. Male sex [72.0%, 46.6%, 40.0%, p = 0.03] and prior perianal surgery [52.0% vs 44.6% vs 40.0%, p = 0.02] were more frequently observed in those with improved class compared to unchanged and worsened class. Baseline pMRI indices were not associated with changes in classification; however, greater improvements in mVAI, MODIFI-CD, and PEMPAC were seen among those who improved. Linear mixed effect modelling identified only male sex [-0.31, 95% CI -0.60 to -0.02] with improvement in class. Conclusion The TOpCLASS classification highlights the dynamic nature of PFCD over time. However, our ability to predict transitions between classes remains limited and requires prospective assessment. Improvement in MRI index scores over time was associated with a transition to lower TOpCLASS classification.
Integration of Telemedicine Consultation Into a Tertiary Radiation Oncology Department: Predictors of Use, Treatment Yield, and Effects on Patient Population
Sharifzadeh, Yasamin , Breen, William G. , Harmsen, William S. , Amundson, A., Garda, Allison E. , Waddle, Mark R. , Merrell, Kenneth W. , Hallemeier, Christopher L. , Laack, Nadia N. , Kollengode, Anantha, Corbin, Kimberly S. , Amundson, Adam C., Routman, David M , Waddle, Mark R , Merrell, Kenneth W , Hallemeier, Christopher Leigh , Laack, Nadia N Issa , Sharifzadeh, Yasamin , Routman, David M.

Mayo Clinic

JCO Clinical Cancer Informatics | April 17, 2024 | Volume: No volume available | Issue: 8 | Pages: No page available

10.1200/cci.23.00239 | PMID 38630957 Get It

PURPOSE The COVID-19 pandemic led to rapid expansion of telemedicine. The implications of telemedicine have not been rigorously studied in radiation oncology, a procedural specialty. This study aimed to evaluate the characteristics of in-person patients (IPPs) and virtual patients (VPs) who presented to a large cancer center before and during the pandemic and to understand variables affecting likelihood of receiving radiotherapy (yield) at our institution. METHODS A total of 17,915 patients presenting for new consultation between 2019 and 2021 were included, stratified by prepandemic and pandemic periods starting March 24, 2020. Telemedicine visits included video and telephone calls. Area deprivation indices (ADIs) were also compared. RESULTS The overall population was 56% male and 93% White with mean age of 63 years. During the pandemic, VPs accounted for 21% of visits, were on average younger than their in-person (IP) counterparts (63.3 years IP v 62.4 VP), and lived further away from clinic (215 miles IP v 402 VP). Among treated VPs, living closer to clinic was associated with higher yield (odds ratio [OR], 0.95; P < .001). This was also seen among IPPs who received treatment (OR, 0.96; P < .001); however, the average distance from clinic was significantly lower for IPPs than VPs (205 miles IP v 349 VP). Specialized radiotherapy (proton and brachytherapy) was used more in VPs. IPPs had higher ADI than VPs. Among VPs, those treated had higher ADI ( P < .001). CONCLUSION Patient characteristics and yield were significantly different between IPPs and VPs. Telemedicine increased reach to patients further away from clinic, including from rural or health care–deprived areas, allowing access to specialized radiation oncology care. Telemedicine has the potential to increase the reach of other technical and procedural specialties.
Timely Completion of Direct Access Colonoscopy Is Noninferior to Office Scheduled for Screening and Surveillance
White, Mary, Israilevich, Rachel , Lam, Sophia , McCarthy, Michael , Mico, Vasil, Chipkin, Benjamin , Abrams, Eric, Moore, Kelly , McCarthy, Michael, Moore, Kelly, Kastenberg, David

Mayo Clinic

Journal of Clinical Gastroenterology | April 17, 2024 | Volume: 59 | Issue: 3 | Pages: 219-226

10.1097/mcg.0000000000002000 | PMID 38630852 Get It

Goals: We aimed to evaluate whether direct access colonoscopy (DAC) is noninferior to office-scheduled colonoscopy (OSC) for achieving successful colonoscopy. Background: DAC may improve access to colonoscopy. We developed an algorithm assessing eligibility, risk for inadequate preparation, and need for nursing/navigator assistance. Study: This was a retrospective, single-center study of DAC and OSC patients from June 5, 2018, to July 31, 2019. Patients were 45 to 75 years old with an indication of screening or surveillance. A successful colonoscopy met 3 criteria: complete colonoscopy (cecum, anastomosis, or ileum), adequate preparation (Boston Score ≥2/segment), and performed <90 days from initial patient contact. Unsuccessful colonoscopy did not meet ≥1 criteria. Secondary end points included days to successful colonoscopy, preparation quality, polyp detection, and 10-year recall rate. Noninferiority against risk ratio value of 0.85 was tested using 1-sided alpha of 0.05. Results: A total of 1823 DAC and 828 OSC patients were eligible. DAC patients were younger, with a greater proportion of black patients and screening indications. For the outcome of successful colonoscopy, DAC was noninferior to OSC (DAC vs. OSC: 62.7% vs. 57.1%, RR 1.16, 95% LCL 1.09, P=0.001). For DAC, days to colonoscopy were fewer, and likelihood of 10-year recall after negative screening greater. Boston Score and polyp detection were similar for groups. Black patients were less likely to achieve successful colonoscopy; otherwise, groups were similar. For unsuccessful colonoscopies, proportionally more DAC patients canceled or no-showed while more OSC patients scheduled >90 days. DAC remained noninferior to OSC at 180 days. Conclusions: DAC was noninferior to OSC for achieving successful colonoscopy, comparing similarly in quality and efficiency outcomes.
Osteochondral Allograft Transplantation to the Capitellum: Technical Considerations of a Mega Osteochondritis Dissecans Technique
Hassebrock, Jeffrey D. , Diduch, David R. , Chhabra, A. Bobby , Hassebrock, Jeffrey D

Mayo Clinic

Arthroscopy Techniques | April 17, 2024 | Volume: 13 | Issue: 7 | Pages: No page available

10.1016/j.eats.2024.102997 | PMID 39100254 Get It

Abstract Osteochondritis dissecans of the elbow is a rare but debilitating pathology typically found in the adolescent repetitive overhead athlete. In the setting of unstable lesions, mechanical symptoms, or deteriorating function despite appropriate conservative management, surgical osteochondral allograft transplantation of the capitellum is a viable option for even large lesions (>10 mm), with minimal morbidity and good return of function. We describe a technique for performing a large osteochondral allograft transplantation of the capitellum. Technique Video video See video under supplementary data.
Placental senescence pathophysiology is shared between peripartum cardiomyopathy and preeclampsia in mouse and human
Roh, Jason D. , Castro, Claire , Yu, Andy, Rana, Sarosh , Shahul, Sajid , Gray, Kathryn J. , Honigberg, Michael C. , Ricke‐Hoch, Melanie , Iwamoto, Yoshiko , Yeri, Ashish, Guerra, Justin Ralph Baldovino , Hobson, Ryan , Chaudhari, Vinita , Chang, Bliss , Sarma, Amy , Lerchenmüller, Carolin , Sayed, Zeina R. Al , Verdugo, Carmen Diaz , Xia, Peng , Skarbianskis, Niv, Zeisel, Amit , Kirkland, James L. , Gorcsan, John , Damp, Julie B., Hanley‐Yanez, Karen , McNamara, Dennis M. , Investigators, for the IPAC, Rosenzweig, Anthony , Fett, James D., Pisarcik, Jessica, McTiernan, Charles F. , Alharethi, Rami , Rasmusson, Kismet, Brunisholz, Kim , Butler, Amy L., Budge, D., Kfoury, Abdallah G., Horne, Benjamin D. , Tuinei, Joe, Brown, Heather , Naftilan, Allen J., Russell, Jill , Freehardt, Darla, Hsich, Eileen , Oblak, Cynthia, Ewald, Greg, Whitehead, Donna, Flanagan, Jean, Platts, Anne, Mullin, Stephanie, Givertz, Michael M. , Anello, Mary Susan, Booth, David R. , Sandlin, Tiffany, Wijesiri, Wendy, Blauwet, Lori A., Brunner, Joann, Phelps, Mary, Kempf, Ruth, Modi, Kalgi , Norwood, Tracy, Griza, Decebal Sorin, Adams, Patricia L., Thohan, Vinay , Wesley-Farrington, Deborah, Soots, Sandra, Sheppard, Richard , Lapointe, Nathalie, Nathaniel, Heather, Kealey, Angela, Semigran, Marc J., Daher, Maureen, Silber, David, Popjes, Eric , Frey, Patricia, Nicklas, Todd, Alexis, Jeffrey D. , Caufield, Lori, Thornton, John W., Gentry, Mindy, Robinson, V.J. , Sharma, Gyanendra K. , Holloway, Joan, Powell, Maria, Markham, David W. , Fernandez, Lynn, Gimovsky, Martin L., Hochbaum, Natalia, Patel, Bharati Kadamb , Adams, Laura , Ramani, Gautam , Robinson, Shawn , Fisher, Stacy D. , Marshall, Joanne, Haythe, Jennifer , Mancini, Donna , Bijou, Rachel, Marks, Marybeth, Arango, Henry, Bolos, Mariana, Mather, Paul , Rubin, Sharon, Bonita, Raphael , Eberwine, Susan, Skopicki, Hal A. , Stergiopoulos, Kathleen , McCathy-Santoro, Ellen, Intravaia, Jennifer, Maas, Elizabeth W., Safirstein, Jordan, Martinez, Nancy , Corpoin, Christine, Hesari, Donna, Chaparro, Sandra , Hudson, Laura J., Ghali, Jalal K. , Injic, Zora, Wittstein, Ilan S. , Kitchen, Robert , Guerra, Justin Baldovino , Chaudhari, Vinita , Chang, Bliss , Sarma, Amy , Al Sayed, Zeina R , Diaz Verdugo, Carmen , Xia, Peng , Zeisel, Amit , Bauersachs, Johann , Kirkland, James L , Karumanchi, S Ananth , Gorcsan, John , Sugahara, Masataka , Hanley-Yanez, Karen , Ellinor, Patrick T , Arany, Zoltan Pierre , McNamara, Dennis M , Rosenzweig, Anthony , Honigberg, Michael C , Castro, Claire , Karumanchi, S. Ananth , Ellinor, Patrick T. , Investigators, for the IPAC, Hilfiker‐Kleiner, Denise , Schelbert, Erik B. , Butler, Amy, Elkayam, Uri , Caro, Jorge , Rajagopalan, Navin , Booth, David, Cooper, Leslie T. , Briller, Joan Ellen , Felker, G. Michael , Kociol, Robb D. , Adams, Patricia, Wells, Gretchen , Michel, Caroline, Boehmer, John , Holloway, Joan, Powell, Maria, Drazner, Mark H. , Zucker, Mark Jay , Baran, David A. , Patel, Bharati, Gottlieb, Stephen S. , Farr, Maryjane , Bozkurt, Biykem , Maas, Elizabeth, Kleet, Audrey

Mayo Clinic

Science Translational Medicine | April 17, 2024 | Volume: 16 | Issue: 743 | Pages: No page available

10.1126/scitranslmed.adi0077 | PMID 38630848 Get It

Peripartum cardiomyopathy (PPCM) is an idiopathic form of pregnancy-induced heart failure associated with preeclampsia. Circulating factors in late pregnancy are thought to contribute to both diseases, suggesting a common underlying pathophysiological process. However, what drives this process remains unclear. Using serum proteomics, we identified the senescence-associated secretory phenotype (SASP), a marker of cellular senescence associated with biological aging, as the most highly up-regulated pathway in young women with PPCM or preeclampsia. Placentas from women with preeclampsia displayed multiple markers of amplified senescence and tissue aging, as well as overall increased gene expression of 28 circulating proteins that contributed to SASP pathway enrichment in serum samples from patients with preeclampsia or PPCM. The most highly expressed placental SASP factor, activin A, was associated with cardiac dysfunction or heart failure severity in women with preeclampsia or PPCM. In a murine model of PPCM induced by cardiomyocyte-specific deletion of the gene encoding peroxisome proliferator–activated receptor γ coactivator-1α, inhibiting activin A signaling in the early postpartum period with a monoclonal antibody to the activin type II receptor improved heart function. In addition, attenuating placental senescence with the senolytic compound fisetin in late pregnancy improved cardiac function in these animals. These findings link senescence biology to cardiac dysfunction in pregnancy and help to elucidate the pathogenesis underlying cardiovascular diseases of pregnancy.